<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540813</url>
  </required_header>
  <id_info>
    <org_study_id>BBM-VS-56</org_study_id>
    <nct_id>NCT00540813</nct_id>
  </id_info>
  <brief_title>Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions</brief_title>
  <acronym>PEPCAD V</acronym>
  <official_title>Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Centre Rotenburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Institute Rotenburg a.d.F.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Centre Rotenburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the feasibility of Paclitaxel-eluting PTCA-balloon&#xD;
      dilation (SeQuent Please) followed by bare metal stent (Coroflex ) deployment in the main&#xD;
      branch (reference diameter: ≥ 2.5 mm and ≤ 3.8 mm, reference diameter of side branch: ≥ 2.0&#xD;
      mm and ≤ 3.5 mm, length of stenoses in either branch ≤ 20 mm) in the treatment of significant&#xD;
      (&gt;70%) de-novo-bifurcation stenoses of any Medina classification type in the native left&#xD;
      coronary artery as reflected by procedural success and to evaluate the preservation of vessel&#xD;
      patency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success (main branch ≤ 30%, side branch ≤ 50%, TIMI Flow 3)</measure>
    <time_frame>acute</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment late lumen loss at 9 months in either branch</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Ischemia</condition>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting balloon</intervention_name>
    <description>drug eluting balloon bifurcated coronary lesions single arm study</description>
    <arm_group_label>Drug Eluting Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris&#xD;
             (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia&#xD;
&#xD;
          -  Women of childbearing potential may not be pregnant nor have the desire to becoming&#xD;
             pregnant during the first year following the study procedure. Hence, patients will be&#xD;
             advised to use an adequate birth control method up to and including 6-month follow-up&#xD;
&#xD;
          -  Patients who are mentally and linguistically able to understand the aim of the study&#xD;
             and to show sufficient compliance in following the study protocol&#xD;
&#xD;
          -  Patients must agree to undergo the 9-month angiographic follow-up&#xD;
&#xD;
          -  Patients must agree to undergo the 3-year clinical follow-up&#xD;
&#xD;
          -  Patient is able to verbally acknowledge and understand the associated risks, benefits,&#xD;
             and treatment alternatives of this trial. The patients, by providing their informed&#xD;
             consent, must agree to these risks and benefits as stated in the patient informed&#xD;
             consent document.&#xD;
&#xD;
        Inclusion Criteria: Lesion Related&#xD;
&#xD;
          -  De-novo bifurcational native left coronary artery lesion (reference diameter LAD or&#xD;
             LCx: 2.5 mm to 3.8 mm, length of stenosis: ≤ 20 mm, reference diameter D1/D2 or&#xD;
             OMS1/OMS2: 2.0 mm to 3.5 mm, length of stenosis: ≤ 20 mm)&#xD;
&#xD;
          -  Diameter stenosis pre procedure must be either more then 70 % in either one or both&#xD;
             branches of the lesion (i.e., bifurcational lesion of any type of the Medina&#xD;
             classification) or more then 50 % if ischemia corresponding to the target lesion is&#xD;
             documented either by exercise stress ECG, stress echocardiography, scintigraphy, MRT,&#xD;
             or suspected based on angina pectoris&#xD;
&#xD;
          -  Single or multi-vessel coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute (&lt; 24 h) or recent (48 hours) myocardial infarction&#xD;
&#xD;
          -  Patients with unstable angina pectoris (Braunwald class 3)&#xD;
&#xD;
          -  Patients with severe congestive heart failure&#xD;
&#xD;
          -  Patients with severe heart failure NYHA IV&#xD;
&#xD;
          -  Patients demonstrating clinical signs of cardiogenic shock at the time of the&#xD;
             procedure (systolic blood pressure of less than 80 mmHg requiring inotropic support,&#xD;
             IABP, and/or fluid challenge)&#xD;
&#xD;
          -  Patients with severe valvular heart disease&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Patients with life expectancy of less than five years or factors making clinical&#xD;
             follow-up difficult&#xD;
&#xD;
          -  Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication&#xD;
             is contraindicated&#xD;
&#xD;
          -  Patients who had a cerebral stroke &lt; 6 months prior to the procedure&#xD;
&#xD;
          -  Patient participates in other clinical trials involving any investigational device or&#xD;
             drug&#xD;
&#xD;
          -  Untreated hyperthyroidism&#xD;
&#xD;
          -  Patient has presence or history of severe renal failure (GFR&lt;30ml/min, &quot;Cockcroft&#xD;
             Gault&quot;) and is therefore at high risk for angiography associated renal complications.&#xD;
             Patient's serum creatinine levels must be documented&#xD;
&#xD;
          -  Post transplantation of any organ or immune suppressive medication&#xD;
&#xD;
          -  Other disease to jeopardize follow-up (e.g., malignancy)&#xD;
&#xD;
          -  Addiction to any drug or to alcohol&#xD;
&#xD;
          -  Patients with any type of surgery during the week preceding the interventional&#xD;
             procedure.&#xD;
&#xD;
          -  Therapy with anticoagulants&#xD;
&#xD;
        Exclusion Criteria: Lesion Related&#xD;
&#xD;
          -  Evidence of extensive thrombosis within target vessel before the intervention&#xD;
&#xD;
          -  Multilesion percutaneous coronary intervention beside the bifurcation lesion in the&#xD;
             left coronary artery (no other intervention is admitted during the same procedure)&#xD;
&#xD;
          -  Patients with another coronary stent implanted previously into the target vessel ≤ 15&#xD;
             mm distant to the current lesion, drug eluting stents less than 9 months and bare&#xD;
             metal stents or stents with passive coatings less than 3 months before the PEPCAD V&#xD;
             BIF&#xD;
&#xD;
          -  Target lesion located in any type of coronary bypass (i.e., venous graft, arterial&#xD;
             bypass) or graft/native artery connection&#xD;
&#xD;
          -  Coronary artery occlusion of any type (e.g., acute or chronic)&#xD;
&#xD;
          -  In-stent restenosis&#xD;
&#xD;
          -  In-segment restenosis of the native vessel within 4 mm adjacent to the target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. G. Mathey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamburg University Cardiovascular Center GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. X. Kleber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine Unfallkrankenhaus Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>F.X.Kleber</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.G: Mathey</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart Centre Rotenburg</investigator_affiliation>
    <investigator_full_name>Ralf Degenhardt, PhD</investigator_full_name>
    <investigator_title>Data Manager</investigator_title>
  </responsible_party>
  <keyword>bifurcation stenosis</keyword>
  <keyword>Patients with documented ischemia due to a de-novo bifurcation stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

